Methods of treating psoriasis with secukinumab
AssigneeNovartis AG
InventorsAchim Guettner, Matthias Machacek, Charis Papavassilis, Oliver Sander
Life of this patent
Estimating the term…
Abstract
The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g. an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
Claims16
A method of treating psoriasis, comprising administering to a patient in need thereof about 75 mg secukinumab by subcutaneous injection at each of weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter.
A method of treating moderate to severe plaque psoriasis, comprising administering to a patient in need thereof about 75 mg secukinumab by subcutaneous injection at each of weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter, wherein the patient weighs less than 70 kg.
A method of treating psoriasis, comprising administering to a patient in need thereof about 75 mg secukinumab by subcutaneous injection weekly for 4 or 5 weeks, and every 4 weeks thereafter.
A method of treating moderate to severe plaque psoriasis, comprising administering to a patient in need thereof about 75 mg secukinumab by subcutaneous injection weekly for 4 or 5 weeks, and every 4 weeks thereafter;
- wherein the patient weights less than 70 kg, and is a candidate for systemic therapy or phototherapy.
Dependencies are inferred from the claim text.